BidaskClub upgraded shares of Emergent Biosolutions, Inc. (NYSE:EBS) from a hold rating to a buy rating in a report released on Friday morning.

Separately, Zacks Investment Research downgraded Emergent Biosolutions from a hold rating to a sell rating in a research note on Monday, July 17th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Emergent Biosolutions has an average rating of Buy and an average price target of $44.00.

Shares of Emergent Biosolutions (NYSE EBS) traded down 0.78% on Friday, hitting $35.81. The stock had a trading volume of 178,722 shares. Emergent Biosolutions has a 52-week low of $24.47 and a 52-week high of $36.95. The firm’s 50-day moving average price is $35.27 and its 200 day moving average price is $31.88. The firm has a market cap of $1.48 billion, a PE ratio of 22.81 and a beta of 1.22.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Zacks’ consensus estimate of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The company had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. The business’s revenue was up 10.4% on a year-over-year basis. On average, equities research analysts predict that Emergent Biosolutions will post $1.55 EPS for the current year.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/26/emergent-biosolutions-inc-ebs-upgraded-to-buy-by-bidaskclub.html.

In other news, Director Jerome M. Hauer sold 10,776 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total transaction of $386,104.08. Following the sale, the director now owns 29,421 shares of the company’s stock, valued at $1,054,154.43. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $35.50, for a total value of $887,500.00. Following the sale, the chairman now directly owns 1,655,216 shares in the company, valued at approximately $58,760,168. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 60,776 shares of company stock valued at $2,186,104. 16.50% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in EBS. Riverhead Capital Management LLC boosted its stake in Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 1,542 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 587 shares during the period. State of Alaska Department of Revenue boosted its stake in Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 100 shares during the period. Creative Planning boosted its stake in Emergent Biosolutions by 1.2% in the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 55 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in Emergent Biosolutions by 17.3% in the first quarter. Envestnet Asset Management Inc. now owns 5,710 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 844 shares during the period. 85.54% of the stock is currently owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.